GLP-1 medications have reshaped the conversation around metabolic health faster than any drug class in a generation. Behind the headlines are two main compounds — semaglutide and tirzepatide — that are often discussed interchangeably despite being meaningfully different molecules. This is a clear-headed look at how they work, where they differ, and what a serious physician-supervised protocol actually looks like.
What GLP-1 Medications Do
GLP-1 (glucagon-like peptide-1) is a hormone your gut produces after eating. It signals the pancreas to release insulin, tells the liver to stop producing glucose, and slows gastric emptying. The net effect is improved blood sugar control and a durable feeling of fullness.
GLP-1 medications are engineered versions of that hormone that last far longer in the body than the natural peptide — days instead of minutes. With weekly injection, the body maintains a continuous signal that it has just eaten, which suppresses appetite, reduces cravings, and produces meaningful changes in weight, blood sugar, and cardiovascular risk markers.
The clinical outcomes at this point are very well documented. Beyond weight loss, there are demonstrated improvements in cardiovascular events, kidney function, sleep apnea, and — in a growing body of research — addiction and inflammation markers.
Semaglutide (Ozempic / Wegovy)
Semaglutide is a GLP-1 receptor agonist — meaning it binds to the GLP-1 receptor only. It is marketed under two brand names by Novo Nordisk:
- Ozempic — FDA-approved for type 2 diabetes, dosed at 0.25 mg to 2 mg weekly
- Wegovy — FDA-approved for weight management, dosed up to 2.4 mg weekly
Both are the same molecule; the brand differentiation is about regulatory approval pathways. Compounded semaglutide, available through licensed pharmacies and physician-supervised programs, is chemically equivalent.
Typical clinical outcomes: 12% to 15% weight reduction over 12 to 18 months, with continued benefit on long-term maintenance.
Tirzepatide (Mounjaro / Zepbound)
Tirzepatide is a dual receptor agonist. It activates both the GLP-1 receptor and the GIP receptor — a second gut hormone that complements GLP-1's effects on insulin sensitivity and fat metabolism. It is marketed by Eli Lilly:
- Mounjaro — FDA-approved for type 2 diabetes
- Zepbound — FDA-approved for weight management
Dual-receptor activity produces notably stronger outcomes. Clinical trials show 20% to 22% weight reduction over 18 months at the highest doses, with improved lipid profiles and better glycemic control compared to semaglutide.
The Real Difference, in Practice
- Magnitude of effect. Tirzepatide produces larger weight loss on average. Semaglutide produces substantial but somewhat smaller effects.
- Side effect profile. Both can cause nausea, constipation, and early-satiety discomfort — especially during dose escalation. Tirzepatide's profile is broadly similar to semaglutide's, with some evidence of milder GI effects at comparable weight-loss endpoints due to the GIP component.
- Cost and supply. Both are expensive at brand-name retail ($900 to $1,400/month). Both have compounded alternatives through licensed pharmacies that make them accessible at a fraction of brand pricing. Supply of brand-name versions has fluctuated since 2023.
- Response variance. Roughly 15% of patients are low responders to GLP-1 alone. Of those, a meaningful fraction respond well to tirzepatide.
Most physicians with experience in both will start a new patient on semaglutide unless there is a specific reason to go directly to tirzepatide (higher BMI, prior partial response, metabolic syndrome comorbidities).
What a Serious Protocol Looks Like
A real physician-supervised GLP-1 program is not just a prescription mailed from a faceless telehealth portal. Minimum expectations:
- Initial consultation with baseline labs — lipids, A1c, comprehensive metabolic panel, thyroid
- Contraindication screening — personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, severe GI motility disorders
- Slow dose escalation — typically 4-week increments to tolerance
- Ongoing monitoring — quarterly check-ins, repeat labs at 6 months
- Nutrition and strength guidance — GLP-1s produce lean-mass loss alongside fat loss if protein intake and resistance training are neglected
- Off-ramp planning — the conversation about long-term maintenance vs. taper should happen at the start, not the end
The clinical outcomes are robust. The clinical delivery varies wildly. This is where supervision matters.
Side Effects to Take Seriously
- GI distress during escalation. Expected. Usually resolves in 2 to 4 weeks at each dose.
- Loss of muscle mass. The quiet risk. Protein intake at 0.8 to 1.0 g per pound of goal bodyweight, plus resistance training 3+ days per week, is the standard mitigation.
- Acute pancreatitis. Rare but documented. Severe or persistent upper abdominal pain warrants immediate evaluation.
- Gallbladder issues. Rapid weight loss of any kind elevates gallstone risk.
- Thyroid nodules. Rare. Baseline ultrasound is reasonable in some risk profiles.
Who GLP-1 Is Not For
- Pregnancy and breastfeeding. No.
- Prior pancreatitis. Usually no.
- Severe gastroparesis. The slowed gastric emptying compounds the condition.
- Eating disorder history. Requires specific clinical judgment — not a general contraindication, but a serious consideration.
GLP-1 medications are not a fad. They are the most significant metabolic intervention in a generation, and when delivered under real physician supervision they produce outcomes that diet and lifestyle alone rarely match. The question is not whether they work — it is whether the program around them is serious enough to produce durable results.